Saltar al contenido principal
xMedica

NCT07439653ClinicalTrials.gov

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

En reclutamientoAdmite participantes ahora, según el registro.
Contactar con este estudio

En resumen

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

Fase 1 / Fase 2155 participantes buscados9 centros1 país

Categorías

Registrado en 1 registro

Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.

La información del ensayo se muestra tal como la publicó el registro, en su idioma original.

¿Le interesa este estudio?

Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-02-27; recorded start 2026-03-31
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Not stated: Open label (no blinding)Masking is recorded as none (open label)
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 9 other studies in this databaseCounted from the lead sponsor named in the record (TORL Biotherapeutics, LLC)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Non-randomised allocation

  • Blinding0/20

    Open-label

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre5/8

    Multi-centre: 3 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleSMALL

A small study: 155 participants (target), run at 9 sites.

How this score is built
  • Enrolment21/40

    155 participants (target)

  • Site count6/25

    3 sites

  • Country count0/15

    Single country

  • Planned duration9/10

    Planned over about 43 months

  • Sponsor scale3/10

    TORL Biotherapeutics, LLC has led 10 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Resumen

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

Afecciones

  • Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Elegibilidad

Elegibilidad
SexoTodos
Edades18 Years – Sin máximo
Voluntarios sanosNo

Elegibilidad tal como figura en el registro

Inclusion Criteria: * Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT. * Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2. * At least 1 measurable lesion per Lugano criteria. * Tumor tissue is available. * Adequate organ function Exclusion Criteria: * T-cell lymphoma * CLL or SL * Burkitt lymphoma and high-grade B-cell lymphoma * CNS involvement * Peripheral neuropathy \> Grade 2 * Uncontrolled medical conditions * Viral infections

Elegibilidad en frases sencillas

Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.

Diseño del estudio

Diseño del estudio
Tipo de estudioDe intervención
FaseFase 1 / Fase 2
AsignaciónNo aleatorizado
Modelo de intervenciónSEQUENTIAL
Propósito principalTREATMENT
EnmascaramientoNONE (0)
Inscripción155 participantes buscados

Patrocinador y colaboradores

  • TORL Biotherapeutics, LLC Patrocinador

Grupos e intervenciones

  • Part 1: Monotherapy Dose EscalationEXPERIMENTAL

    TORL-5-700 Administered once every three weeks

  • Part 2: Monotherapy ExpansionEXPERIMENTAL

    TORL-5-700 at MTD/RP2D Administered once every three weeks

  • Part 3: Combination EvaluationEXPERIMENTAL

    TORL-5-700 at MTD/RP2D Administered once every three weeks in combination with another agent

Intervenciones

  • Fármaco TORL-5-700

    Part 1: Monotherapy Dose Escalation - TORL-5-700 Administered once every three weeks

  • Fármaco TORL-5-700 at MTD/RP2D

    Part 2: Monotherapy Expansion - TORL-5-700 at Maximum tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) Administered once every three weeks

  • Fármaco TORL-5-700 at MTD/RP2D in combination with another agent

    Part 3: Combination Evaluation - TORL-5-700 at MTD/RP2D administered every three weeks in combination with another agent

Variables de resultado

  1. Variable de resultado principal

    Evaluate the safety of TORL-5-700 as a monotherapy

    Assessment of adverse events according to NCI-CTCAE Version 5.0

    Plazo though study completion, an average of 2.5 years

  2. Variable de resultado principal

    Assess the antitumor activity of TORL-5-700 as monotherapy

    Assess the antitumor activity of TORL-5-700 using Cheson (2014) disease grading criteria

    Plazo though study completion, an average of 2.5 years

  3. Variable de resultado principal

    Evaluate the safety of TORL-5-700 in combination with other agents

    Assessment of adverse events according to NCI-CTCAE Version 5.0

    Plazo though study completion, an average of 2.5 years

  4. Variable de resultado principal

    Determine the Maximum Tolerated Dose (MTD)

    Determine the MTD by assessing Protocol defined Dose Limiting Toxicities (DLT)

    Plazo 21 days from the start of treatment

  5. Variable de resultado principal

    Determine the Recommended Phase 2 Dose (RP2D)

    Determine the RP2D by assessing Protocol defined Dose Limiting Toxicities

    Plazo 21 days from the start of treatment

  6. Variable de resultado secundaria

    Maximum Serum Concentration of TORL-5-700 (Cmax)

    Pk assessment

    Plazo though end of study treatment, an average of 5 months

  7. Variable de resultado secundaria

    Maximum Serum Concentration of TORL-5-700 (Cmax) in combination with other agents

    Pk assessment

    Plazo though end of study treatment, an average of 5 months

  8. Variable de resultado secundaria

    Terminal Half-life (t1/2) of Serum TORL-5-700

    Pk assessment

    Plazo though end of study treatment, an average of 5 months

  9. Variable de resultado secundaria

    Terminal Half-life (t1/2) of Serum TORL-5-700 in combination with other agents

    Pk assessment

    Plazo though end of study treatment, an average of 5 months

  10. Variable de resultado secundaria

    Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration

    Pk assessment

    Plazo though end of study treatment, an average of 5 months

  11. Variable de resultado secundaria

    Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration in combination with other agents

    Pk assessment

    Plazo though end of study treatment, an average of 5 months

  12. Variable de resultado secundaria

    Clearance (CL) of TORL-5-700

    Pk assessment

    Plazo though end of study treatment, an average of 5 months

  13. Variable de resultado secundaria

    Clearance (CL) of TORL-5-700 in combination with other agents

    Pk assessment

    Plazo though end of study treatment, an average of 5 months

  14. Variable de resultado secundaria

    Volume of distribution of TORL-5-700

    PK assessment

    Plazo though end of study treatment, an average of 5 months

  15. Variable de resultado secundaria

    Volume of distribution of TORL-5-700 in combination with other agents

    PK assessment

    Plazo though end of study treatment, an average of 5 months

  16. Variable de resultado secundaria

    Immunogenicity of TORL-5-700

    Immunogenicity will be measured by incidence of treatment emergent ADAs

    Plazo though end of study treatment, an average of 5 months

  17. Variable de resultado secundaria

    Immunogenicity of TORL-5-700 in combination with other agents

    Immunogenicity will be measured by incidence of treatment emergent ADAs

    Plazo though end of study treatment, an average of 5 months

  18. Variable de resultado secundaria

    Assess the preliminary antitumor activity of TORL-5-700 in combination with other agents

    Assess the antitumor activity of TORL-5-700 in combination with other agents using Cheson (2014) disease grading criteria

    Plazo though study completion, an average of 2.5 years

Fechas

Fechas
Fecha de inicio31 de marzo de 2026 (real)
Finalización principal31 de marzo de 2029 (estimada)
Finalización30 de septiembre de 2029 (estimada)
Primera publicación27 de febrero de 2026 (real)
Última actualización28 de septiembre de 2026
Resultados publicadosNo indicado en el registro
Estado verificado por última vezagosto de 2026

Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.

Ubicaciones

9 centros están en reclutamiento

United States

United States
CentroCiudadEstado o regiónEstado
University of Texas Southwestern Medical CenterDallasTexasEn reclutamiento
Providence Medical FoundationFullertonCaliforniaEn reclutamiento
University of Iowa Health CareIowa CityIowaEn reclutamiento
Cancer and Blood Specialty Clinic, Los AlamitosLos AlamitosCaliforniaEn reclutamiento
University of California Miami, Sylvester Comprehensive Cancer CenterMiamiFloridaEn reclutamiento
Sarah Cannon Research InstituteNashvilleTennesseeEn reclutamiento
UCLASanta MonicaCaliforniaEn reclutamiento
Stanford UniversityStanfordCaliforniaEn reclutamiento
Cancer Center of Kansas, WichitaWichitaKansasEn reclutamiento

Documentos del estudio

No hay documentos enlazados en este registro.

Cambios a lo largo del tiempo

  1. 28 de septiembre de 2026

    Centro añadido

    3 sites added (9 total)

    69

  2. 24 de agosto de 2026

    Centro añadido

    3 sites added (6 total)

    36